Login to Your Account



When Patents Expire

PDL BioPharma Deploys Cash To Create New Income Streams

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, October 22, 2012

After selling off its commercial and cardiovascular operating segments and spinning the remaining R&D operations into Facet Biotech Corp., PDL BioPharma Inc. became dependent on royalties from humanized antibody products covered under licenses of its Queen et al. patents.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription